Q2 2021 Financial Results

AbbVie raises full-year 2021 EPS guidance with strong performance across our diverse portfolio.

Learn more

Our History

Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.

Learn more

Latest news

If you are a member of the news media and have questions or need additional information, please contact our communications team.

Aug 04, 2021

JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis

Jul 30, 2021

AbbVie Reports Second-Quarter 2021 Financial Results

Jul 29, 2021

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

Jul 27, 2021

AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?